Component-level research for the Wolverine blend
Wolverine combines BPC-157 and TB-500; the most defensible research view is therefore component-specific, not a claim that the finished blend has been directly studied.
Overview
Wolverine is a two-component research blend containing BPC-157 and TB-500. No peer-reviewed study located in this evidence review evaluated the VIVO blend as a combined material. The references below therefore address the identity, detection, metabolism, and cell-level activity reported for its individual components.
For BPC-157, analytical studies have used mass spectrometry to identify the parent sequence and related fragments formed under controlled in vitro conditions. For the thymosin beta-4-derived component, laboratory work has examined actin binding and the effect of an LKKTETQ-containing peptide on endothelial-cell migration and tube formation.
These sources provide a practical basis for component verification and experimental design. They should not be read as evidence of synergy, compatibility, stability, or a predictable combined response for Wolverine. Those questions require direct study of the finished blend under a defined protocol.
References
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.
- Cox HD, Miller GD, Eichner D (2017). Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Testing and Analysis; 9(10):1490–1498. View source ↗
- Tian T, Jing J, Li Y, et al. (2023). Stable isotope labeling-based characterization of the in vitro metabolic profile of BPC-157 by UHPLC-HRMS. Molecules; 28(21):7345. View source ↗
- Philp D, Huff T, Gho YS, et al. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote endothelial cell differentiation and migration. Journal of Cellular Physiology; 196(1):146–156. View source ↗